Loading
P2RY8 (S-geranylgeranyl-glutathione receptor P2RY8) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Diffuse large B-cell lymphoma and 1 more.
G protein-coupled receptor for S-geranylgeranyl-glutathione (GGG), an endogenous metabolite present in lymphoid tissues. Couples the binding of GGG to the activation of GNA13 and downstream repression of AKT activation in lymphocytes defining their positioning and growth within lymphoid organs. In lymphoid follicles, confines B cells and follicular helper T cells in germinal centres (GCs) in response to GGG local gradients established by GGT5 (via GGG catabolism) and ABCC1 (via extracellular transport) with lower concentrations of GGG found in the follicular dendritic cell network region around which germinal centres are formed.
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.59 (direct and indirect evidence; datatypes literature 0.22, somatic mutation 0.96). IntOGen calls it a driver in 8 cohorts (5 activating, 3 loss-of-function), covering Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma.
In plain words · P2RY8 (S-geranylgeranyl-glutathione receptor P2RY8) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Diffuse large B-cell lymphoma and 1 more.
P2RY8 (S-geranylgeranyl-glutathione receptor P2RY8) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Diffuse large B-cell lymphoma and 1 more.
G protein-coupled receptor for S-geranylgeranyl-glutathione (GGG), an endogenous metabolite present in lymphoid tissues.
No product in this corpus aims at P2RY8 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA P2RY8: RNA group enriched (bone marrow 29 nTPM, lymphoid tissue 37 nTPM); no normal tissue stained high. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Lung cancer (all types)); Open Targets associates it with 1 specific cancer type at or above 0.5 (diffuse large B-cell lymphoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q86VZ1; CIViC gene P2RY8; IntOGen P2RY8; Human Protein Atlas P2RY8 tissue; Open Targets ENSG00000182162 associations
First described 2004. Earliest sequence paper UniProt cites for the protein: Genome Res, 2004, "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)". Source.
Sources: HGNC HGNC:15524 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q86VZ1 (protein name, function text, keywords and locations (REST API)); CIViC gene P2RY8 (2 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma, Burkitt Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000182162 (association with cancer (MONDO_0004992) 0.59; per-cancer scores at or above 0.5: diffuse large B-cell lymphoma 0.65, non-Hodgkin lymphoma 0.69, non-Hodgkin lymphoma 0.53, lung cancer 0.51 (GraphQL API, CC0)); IntOGen P2RY8 (driver in 8 cohorts (Act 5, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
G protein-coupled receptor for S-geranylgeranyl-glutathione (GGG), an endogenous metabolite present in lymphoid tissues. Couples the binding of GGG to the activation of GNA13 and downstream repression of AKT activation in lymphocytes defining their positioning and growth within lymphoid organs. In lymphoid follicles, confines B cells and follicular helper T cells in germinal centres (GCs) in response to GGG local gradients established by GGT5 (via GGG catabolism) and ABCC1 (via extracellular transport) with lower concentrations of GGG found in the follicular dendritic cell network region around which germinal centres are formed. In the bone marrow, also in response to GGG gradients established by GGT5 and ABCC1, it restricts chemotactic transmigration of B cells, T cells and NK cells from blood vessels to the bone marrow parenchyma. Contributes to GNA13-dependent pathway that suppresses GC B cell growth. Location: Cell membrane (UniProt). Locus Xp22.33 and Yp11.3 (HGNC).
RNA: group enriched (bone marrow 29 nTPM, lymphoid tissue 37 nTPM), detected in many normal tissues.
No normal tissue stained high; medium in Lymph node, Tonsil.
RNA cancer enhanced: Kidney Renal Clear Cell Carcinoma 12 pTPM.
No cancer stained high; medium in lymphoma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"P2RY8" OR ABSTRACT:"P2RY8" OR TITLE:"P2Y receptor family member 8" OR ABSTRACT:"P2Y receptor family member 8" OR TITLE:"S-geranylgeranyl-glutathione receptor P2RY8" OR ABSTRACT:"S-geranylgeranyl-glutathione receptor P2RY8" OR TITLE:"P2Y8" OR ABSTRACT:"P2Y8") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about P2RY8, not a curated reading list.
Shares Burkitt lymphoma, CIViC, IntOGen, Diffuse large B-cell lymphoma.
Shares Burkitt lymphoma, CIViC, IntOGen, Diffuse large B-cell lymphoma.
Shares Burkitt lymphoma, CIViC, IntOGen, Diffuse large B-cell lymphoma.
Shares Burkitt lymphoma, CIViC, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Burkitt lymphoma, CIViC, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Burkitt lymphoma, CIViC, IntOGen, Diffuse large B-cell lymphoma.
Shares Burkitt lymphoma, CIViC, IntOGen, Diffuse large B-cell lymphoma.
Shares Burkitt lymphoma, CIViC, IntOGen, Non-Hodgkin lymphoma (all types).